Retracted: A comparative study of propranolol versus amitriptyline at a low dose for prophylaxis of episodic migraine at a tertiary care centre

Nasra Banu; Iram Shaifali; Shalini Chandra; Anju Saxena

doi:10.18203/2319-2003.ijbcp20242418

Authors

Nasra Banu Department of Pharmacology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India
Iram Shaifali Department of Pharmacology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India
Shalini Chandra Department of Pharmacology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India
Anju Saxena Department of Pharmacology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20242418

Keywords:

Amitriptyline, Efficacy, Episodic migraine, Prophylaxis, Propranolol, Tolerability

Abstract

The article "A comparative study of propranolol versus amitriptyline at a low dose for prophylaxis of episodic migraine at a tertiary care centre" has been retracted by the Editor-in-Chief due to violations of the policies and practices of the International Journal of Basic & Clinical Pharmacology. The retraction follows a complaint from the study institution regarding the presentation of false information in the study details, issues with ethical approval, and discrepancies in authorship.

Metrics

Metrics Loading ...

References

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-45.

Headaches in over 12s: diagnosis and management. National Institute for Health and Care Excellence. 2012. Available at: www.nice.org.

Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. CJNS. 2012;39(2):1-59.

Pharmacological management of migraine. Scottish Intercollegiate Guidelines Network (SIGN). 2018. Available at: www.sign.ac. Accessed from 28th March 2024.

Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann. Indian Acad. Neurol. 2011;14(1):40-59.

Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Baten. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963-74.

The use of the WHO–UMC system for standardized case causality assessment. Available at: http://www.WHO-UMC.org/graphic. Accessed from 28th March 2024.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49:2229–32.

Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache. 1981;21(3):105-9.

Islam M, Sultana D, Shahi M, Hassan M. Comparison of Propranolol and Amitriptyline as Monotherapy for Migraine Prophylaxis. JCAMR. 2019;6:77-82.

Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia: An International Journal of Headache. 2014;34(7):523-32.

Al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo-controlled study. Cephalalgia: An International Journal of Headache. 1993;13(2):128-31.

Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. Trans Am Neurol Assoc. 1976;101:234-7.